Tvardi Therapeutics (TVRD) Stock Chart & Stock Price History $22.74 -3.37 (-12.91%) As of 07/16/2025 04:00 PM Eastern Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesSEC FilingsTrendsBuy This Stock Tvardi Therapeutics Stock Price Performance The Tvardi Therapeutics (TVRD) stock chart highlights key performance trends across multiple timeframes. In the past month, the stock has decreased 9.29%, reflecting recent market activity. As of the latest close, Tvardi Therapeutics traded at $22.74 with a market cap of $212.87 million and volume of 57,131 shares. Receive TVRD Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Tvardi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance-16.83%1 Month Performance-9.29% TVRD Stock Chart for Thursday, July, 17, 2025 TVRD Chart by TradingView Tvardi Therapeutics Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization07/16/2025$26.11$22.74-12.91%$25.06$22.7457,131 shs$212.87 million07/15/2025$29.83$26.11-12.47%$30.00$26.0147,545 shs$244.39 million07/14/2025$27.34$29.83+9.11%$31.98$26.6472,682 shs$279.21 million07/11/2025$22.67$27.34+20.60%$27.79$23.0096,236 shs$255.90 million07/10/2025$22.13$22.67+2.44%$22.85$21.8619,929 shs$212.21 million07/09/2025$21.85$22.13+1.28%$22.17$21.3417,989 shs$207.14 million07/08/2025$21.52$21.85+1.53%$22.00$21.1725,737 shs$204.52 million07/07/2025$22.46$21.52-4.19%$22.21$21.1416,890 shs$201.43 million07/04/2025$22.46$22.46$22.47$21.1519,658 shs$210.23 million07/03/2025$21.45$22.46+4.71%$22.47$21.1519,658 shs$210.23 million Get the Latest News and Ratings for TVRD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Tvardi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 07/02/2025$22.15$21.45-3.16%$22.44$21.1436,465 shs$200.79 million07/01/2025$23.33$22.15-5.06%$23.34$22.0336,194 shs$207.32 million06/30/2025$24.61$23.33-5.20%$24.61$22.4656,807 shs$218.37 million06/27/2025$25.21$24.61-2.38%$25.59$23.89515,028 shs$230.35 million06/26/2025$27.11$25.21-7.01%$27.27$24.6551,032 shs$235.97 million06/25/2025$28.52$27.11-4.94%$28.73$26.6040,879 shs$253.75 million06/24/2025$25.38$28.52+12.37%$28.62$25.0594,798 shs$266.95 million06/23/2025$25.77$25.38-1.51%$26.37$24.1099,833 shs$237.58 million06/20/2025$25.59$25.77+0.70%$26.49$24.36411,634 shs$241.21 million06/19/2025$25.59$25.59$25.98$24.5093,864 shs$239.52 million06/18/2025$25.07$25.59+2.07%$25.98$24.5093,864 shs$239.55 million06/17/2025$24.96$25.07+0.44%$26.71$24.4296,586 shs$234.68 million06/16/2025$24.62$24.96+1.38%$25.73$24.4335,574 shs$233.65 million Related Companies GH Research Stock Price Chart Replimune Group Stock Price Chart Syndax Pharmaceuticals Stock Price Chart Xeris Biopharma Stock Price Chart Vir Biotechnology Stock Price Chart Cronos Group Stock Price Chart Oculis Stock Price Chart Chimerix Stock Price Chart CorMedix Stock Price Chart uniQure Stock Price Chart Receive TVRD Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Tvardi Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:TVRD) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tvardi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tvardi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
